statnews.com·Jun 9, 2026
GSK has acquired Nuvalent, a biotech company focused on targeted cancer therapies, for $10.6 billion, enhancing its lung cancer portfolio ahead of FDA decisions on two of Nuvalent's drugs. The latest biotech news also includes trial results from Gilead and Merck.
GSK's acquisition of Nuvalent for $10.6 billion is a significant move, expanding its portfolio in lung cancer treatments with two FDA-reviewed drugs targeting genetic mutations. This highlights the importance of strategic acquisitions in biotech to enhance capabilities in precision medicine and suggests a potential investment opportunity or partnership focus in oncology drug development.